Synthesis and antitumor activity of a series of novel N-aryl-5-(2, 2, 2-trifluoroethoxy)-1, 5-dihydro-2H-pyrrol-2-ones derivatives. (1st October 2022)

• Record Type: Journal Article
• Authors: Li, Bin; Hu, Mingli; Chen, Chen; Yin, Honglu; Deng, Yan; Li, Haibo; Zhang, Jing; He, Ling
• Is Part Of: Bioorganic & medicinal chemistry letters. Volume 73(2022)
• Publication Date: 2022-10-01
• Subjects: 1-Phenyl-1, 5-dihydro-2H-pyrrol-2-ones -- Antitumor activity -- Transition metal catalysis; Bioorganic chemistry -- Periodicals; Pharmaceutical chemistry -- Periodicals; 572
• DOI: 10.1016/j.bmcl.2022.128919
• Languages: English
• ISSNs: 0960-894X

Abstract

Graphical abstract: Abstract: With the help of the establishment of novel reaction methodology, a series of N -Aryl-5-(2, 2, 2-trifluoroethoxy)-1, 5-dihydro-2 H -pyrrol-2-one conjugates were designed and synthesized in 2–4 steps, and subsequent anticancer activity of these compounds was evaluated. Preliminary results showed that these compounds have moderate to potent activities against human acute leukemia cells K562, human lung cancer A549, human breast cancer MDA-MB-231, and human cervical cancer HeLa cancer cell lines. Among them, compounds 2d and 2k were the most potent against K562 cell line with IC50 values of 0.07 and 0.52 µM, respectively, and the toxicity of 2d to the normal of hepatocytes (LO2) cell line was low (the survival rate 81 %). Flow cytometry analysis showed that 2d arrested K562 cells in the G2/M phase potently, even much better than Combretastatin A4 (CA4). In addition, the results demonstrated the involvement of the caspase-dependent or independent pathways of apoptosis, evidenced by the upregulation of FADD, pro-caspase 3, cleaved-caspase 3, HTRA2/Omi, SMAC/Diablo and the ratio of Bax/Bcl-2.The biological effects founding of 2d in this work point to prospective uses against acute leukemia.